Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Ludwig Kappos(Novartis (Switzerland)), Rupert Sandbrink(Io Therapeutics (United States)), Peter Jakobs, Christoph Pohl, Frederik Barkhof(Netherlands Institute for Neuroscience), HP Hartung(Heinrich Heine University Düsseldorf), Gilles Edan(Centre National de la Recherche Scientifique), David H. Miller(National Hospital for Neurology and Neurosurgery), Chris H. Polman(Vrije Universiteit Amsterdam), Mark S. Freedman(University of Ottawa), Lars Bauer(UCB Pharma (Germany)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 551
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k